(Q33384877)

26 July 2017

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma (English)

1 reference

metastatic hepatocellular carcinoma

26 July 2017

1 reference

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

1 reference

1 reference

J O Lee

1

1 reference

26 July 2017

K W Lee

2

1 reference

26 July 2017

D Y Oh

3

1 reference

26 July 2017

J H Kim

4

1 reference

26 July 2017

S A Im

5

1 reference

26 July 2017

T Y Kim

6

1 reference

26 July 2017

Y J Bang

7

1 reference

26 July 2017

5 June 2009

1 reference

26 July 2017

1 reference

26 July 2017

20

1 reference

26 July 2017

8

1 reference

26 July 2017

1402-1407

1 reference

26 July 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP010

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP010

1 reference

26 July 2017

1 reference